Physician profile
Jan Slomba
NPI 1689658007
$3,146.13
in general payments reported to CMS, 2019-2025
24 companies · $693 in 2025
The $693 reported for 2025 was more than what a typical Pain Medicine provider received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $629 · 2020: $418 · 2021: $591 · 2022: $202 · 2023: $101 · 2024: $514 · 2025: $693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,307.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,307.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,499.17 | 2019-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $595.90 | 2019-2025 | Xtampza |
| Pfizer INC. | $223.70 | 2019-2025 | |
| Biodelivery Sciences International, INC. | $221.56 | 2019-2021 | |
| Forte Bio-Pharma LLC | $111.57 | 2021-2024 | Prolate, Nalocet |
| Biohaven Pharmaceuticals, INC. | $66.11 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $60.11 | 2022 | |
| Sentynl Therapeutics, INC. | $49.74 | 2019-2020 | |
| Assertio Therapeutics, INC. | $46.58 | 2019 | |
| Scilex Pharmaceuticals INC. | $23.61 | 2022 | |
| Sunovion Pharmaceuticals INC. | $23.52 | 2020 | |
| Boston Scientific Corporation | $20.83 | 2020 | |
| Idorsia Pharmaceuticals US INC | $20.10 | 2025 | Quviviq |
| Protega Pharmaceutials INC | $19.67 | 2024 | Roxybond |
| Horizon Therapeutics Plc | $19.33 | 2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $18.90 | 2024 | |
| Si-Bone, INC. | $18.30 | 2024 | |
| Redhill Biopharma INC. | $18.25 | 2021 | |
| Vertical Pharmaceuticals, LLC | $17.04 | 2019 | |
| Shionogi INC | $16.63 | 2019 | |
| Valinor Pharma, LLC | $15.36 | 2025 | Movantik |
| Teva Pharmaceuticals USA, INC. | $15.00 | 2019 | |
| Almatica Pharma LLC | $14.13 | 2021 | |
| Daiichi Sankyo INC. | $11.02 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Slomba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.